Idania Baladrón

CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo

Silvio E. Perea, Osvaldo Reyes, Idania Baladrón et al. · Molecular and Cellular Biochemistry · 2008 · 99 citations

Ck2 Phosphorylation, Novel Proapoptotic Peptide, Signal Transduction +11

Safety and preliminary efficacy data of a novel Casein Kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies

Ana M. Solares, Agueda Santana, Idania Baladrón et al. · BMC Cancer · 2009 · 80 citations · Full text

Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial

Leticia Rosario Cruz, Idania Baladrón, Aliusha Rittoles et al. · ACS Pharmacology & Translational Science · 2020 · 45 citations · Full text

CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research

Silvio E. Perea, Idania Baladrón, Yanelda García et al. · Molecular and Cellular Biochemistry · 2011 · 43 citations

Molecular Pharmacology, Signal Transduction, Ck2 Phosphoaceptor Domain +12

Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial

Ana M. Solares, Idania Baladrón, Thelvia I. Ramos et al. · ISRN Obstetrics and Gynecology · 2011 · 42 citations · Full text